Атипичный гемолитико-уремический синдром у детей

Tamara P. Makarova, Khadizha M. Emirova, Дмитрий Владимирович Зверев et al. · Practical medicine · 2012

Atypical HUS (aHUS) — a disease caused by dysregulation of the alternative pathway activation of complement. The criteria for the diagnosis of aHUS are: 1) the absence of associated diseases, 2) the lack of criteria for HUS associated with Shiga toxin, 3) lack of criteria for thrombotic thrombocytopenic purpura. To date, the first-line therapy is plasma therapy. A new therapeutic option in the world today has been the use of monoclonal antibodies inhibitors of the complement system (complement component C5 blocker). The only representative of this group is the drug eculizumab (Soliris). aHUS designates a primary disease due to a disorder in complement alternative pathway regulation. Diagnosis of aHUS relies on 1) No associated disease 2) No criteria for Shigatoxin-HUS 3) No criteria for thrombotic thrombocytopenic purpura (serum ADAMTS 13 activity > 10%). Plasmatherapy has been first line treatment until presently. New approach in therapy of aHUS is application of Eculizumab — inhibitor of C5 of component of complement.

Cited by 0 works.

Authors